Compare KORE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | ONCY |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | Canada |
| Employees | 539 | 29 |
| Industry | Telecommunications Equipment | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 98.7M |
| IPO Year | N/A | 2002 |
| Metric | KORE | ONCY |
|---|---|---|
| Price | $9.18 | $0.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $7.33 |
| AVG Volume (30 Days) | 28.9K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.33 |
| 52 Week High | $9.22 | $1.51 |
| Indicator | KORE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 33.09 |
| Support Level | $4.10 | N/A |
| Resistance Level | $9.22 | $1.18 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 51.62 | 12.01 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.